Published in Gene Therapy Weekly, October 28th, 2004
This therapy will be based on Oriel Therapeutics' proprietary dry powder inhalation technology incorporating the partner's proprietary compounds that represent a novel mode of action to improve airway function.
Cystic fibrosis is a genetic disorder that affects approximately 30,000 children and adults in the United States. The disease causes the body to produce abnormally thick, sticky mucus that clogs the lungs and leads to life-threatening...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.